AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 181 min read$RARE

Ultragenyx Shares Rise After Hours Following FDA Approval - Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose 2.55% in after-hours trading on Thursday after the FDA approved FAYUVI, the first treatment for Sanfilippo syndrome Type A. The approval is based on clinical trial data showing significant cognitive improvements. Ultragenyx's market cap is $1.43 billion, with shares down 50.19% over the past year.

Original reporting
benzinga.com
Published Sep 18, 2026, 4:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 4:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ultragenyx Shares Rise After Hours Following FDA Approval - Ultragenyx Pharmaceutical (NASDAQ:RARE) — source image
Source · benzinga.com
Decision brief

The 30-second read

$RAREBullishHigh
01

Why it matters

The approval may drive immediate share price appreciation and attract investor interest in rare‑disease pipelines.

02

Market read

Regulatory approval of a first‑in‑class therapy is a high‑impact event for the stock and the broader biotech sector.

03

What to watch

Manufacturing scale‑up and payer acceptance timelines may delay revenue realization.

Relevance 8/10Novelty 9/10Timing: after‑hours today

Background

Ultragenyx is a California‑based biotech focused on rare diseases; this is its second gene‑therapy approval.

Company-level read

Ticker impact

$RAREBullishHigh confidence
Context

FDA granted full approval for Ultragenyx's gene therapy FAYUVI, the first treatment for Sanfilippo syndrome Type A.

Expected impact

Potential upside of 5‑10% in the next few trading sessions.

Evidence & confidence

Regulatory clearance for a novel, ultra‑rare therapy is a material catalyst for a biotech with limited pipeline.

Market effects

Sector

Strengthens the gene‑therapy segment and may boost peer biotech valuations.

Regional

Positive for US biotech sector; limited global ripple.

Global

Highlights FDA's role in advancing rare‑disease treatments.

Counterpoint

What could challenge this read

Potential pricing pressure and reimbursement challenges could limit upside.

Key entities

  • Company
    Ultragenyx Pharmaceutical Inc.

    Developer of FAYUVI gene therapy.

  • Regulatory Agency
    FDA

    Granted full approval for the therapy.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 18
$BBMed

S&P 500, Nasdaq, Dow Set For Mixed Open? US Stock Futures Seek Direction After Fed's First Rate Hike In Three Years

US stock futures were mixed after the Fed's first rate hike in three years. Brent crude and WTI oil prices fell, while Treasury yields declined. BlackBerry (BB) rose on a partnership announcement, CoreWeave (CRWV) gained on new contracts and capital raises, and Ultragenyx (RARE) surged after FDA approval. Uber (UBER) was in focus due to a rival's robotaxi partnership. Asian markets opened higher.

finance.yahoo.com2 min
SEP 17
$RAREHighAI 9/10

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy

Ultragenyx Pharmaceutical Inc. (RARE) shares rose 13% during trading and 3% after-hours after the FDA approved Fayuvi, a gene therapy for Sanfilippo syndrome type A. The stock had previously hit a 52-week low. The therapy, priced at $3.95 million per patient, is Ultragenyx's second gene therapy approval. Retail sentiment on Stocktwits turned 'extremely bullish'.

stocktwits.com2 min
SEP 17
$RAREHighAI 9/10

RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo

Ultragenyx (RARE) received FDA approval for its gene therapy Fayuvi, the first treatment for Type A Sanfilippo syndrome. The company's P/S ratio is 2.09, below its historical median of 16.1x. GuruFocus estimates RARE is 68.1% undervalued at $14.50 per share, but notes risks due to ongoing losses and cash burn. Insiders have sold $4.0M in shares in the past year.

gurufocus.com3 min
SEP 17
$RAREHighAI 9/10

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the

SEC EDGAR 8-K1 min
SEP 17
$RAREHighAI 9/10

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx Pharmaceutical (RARE) shares rose 10% after the FDA approved Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This is the first FDA-authorized treatment for this rare pediatric disease. The therapy showed improved cognitive function in clinical trials but carries risks like liver enzyme increases and potential long-term tumor development.

investing.com2 min